Short Interest in bioAffinity Technologies, Inc. (NASDAQ:BIAF) Expands By 148.8%

bioAffinity Technologies, Inc. (NASDAQ:BIAF) was the recipient of a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 62,700 shares, an increase of 148.8% from the February 29th total of 25,200 shares. Currently, 1.8% of the shares of the stock are short sold. Based on an average daily trading volume, of 162,400 shares, the days-to-cover ratio is presently 0.4 days.

bioAffinity Technologies Stock Down 3.8 %

Shares of BIAF traded down $0.08 during mid-day trading on Thursday, reaching $2.00. The company had a trading volume of 59,286 shares, compared to its average volume of 173,274. The company’s 50 day simple moving average is $1.77 and its 200 day simple moving average is $1.55. bioAffinity Technologies has a 1-year low of $0.95 and a 1-year high of $3.62. The company has a current ratio of 3.07, a quick ratio of 3.06 and a debt-to-equity ratio of 0.13.

Institutional Investors Weigh In On bioAffinity Technologies

A number of hedge funds have recently made changes to their positions in BIAF. Jane Street Group LLC acquired a new stake in bioAffinity Technologies during the 3rd quarter worth approximately $32,000. State Street Corp bought a new position in bioAffinity Technologies during the 1st quarter worth approximately $33,000. Citadel Advisors LLC bought a new position in bioAffinity Technologies during the 3rd quarter worth approximately $60,000. Finally, Two Sigma Investments LP bought a new position in bioAffinity Technologies during the 1st quarter worth approximately $50,000. 1.64% of the stock is currently owned by institutional investors and hedge funds.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.